Mirtazapine hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 577449

CAS#: 207516-99-2

Description: Mirtazapine hydrochloride is an atypical antidepressant with noradrenergic and specific serotonergic activity.

Chemical Structure

img
Mirtazapine hydrochloride
CAS# 207516-99-2
Instruction

Theoretical Analysis

MedKoo Cat#: 577449
Name: Mirtazapine hydrochloride
CAS#: 207516-99-2
Chemical Formula: C17H20ClN3
Exact Mass: 301.13
Molecular Weight: 301.820
Elemental Analysis: C, 67.65; H, 6.68; Cl, 11.75; N, 13.92

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Mirtazapine hydrochloride; Mirtazapine HCl

IUPAC/Chemical Name: Pyrazino(2,1-a)pyrido(2,3-C)(2)benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, hydrochloride (1:1)

InChi Key: SISMRXGXKXMBKT-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H19N3.ClH/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20;/h2-8,16H,9-12H2,1H3;1H

SMILES Code: Cl.CN1CCN2C(C1)c3ccccc3Cc4cccnc24

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 301.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Praharaj SK, Kongasseri S, Behere RV, Sharma PS. Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol. 2015 Oct;5(5):307-13. doi: 10.1177/2045125315601343. Review. PubMed PMID: 26557987; PubMed Central PMCID: PMC4622124.

2: Verster JC, van de Loo AJ, Roth T. Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability. Eur J Pharmacol. 2015 Apr 15;753:252-6. doi: 10.1016/j.ejphar.2014.10.032. Epub 2014 Nov 13. Review. PubMed PMID: 25446559.

3: Holland J, Bhogle M. Sertraline and mirtazapine as geriatric antidepressants. Psychiatr Danub. 2013 Sep;25 Suppl 2:S286-90. Review. PubMed PMID: 23995195.

4: Graves SM, Rafeyan R, Watts J, Napier TC. Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside. Pharmacol Ther. 2012 Dec;136(3):343-53. doi: 10.1016/j.pharmthera.2012.08.013. Epub 2012 Aug 29. Review. PubMed PMID: 22960395; PubMed Central PMCID: PMC3483434.

5: Dolder CR, Nelson MH, Iler CA. The effects of mirtazapine on sleep in patients with major depressive disorder. Ann Clin Psychiatry. 2012 Aug;24(3):215-24. Review. PubMed PMID: 22860241.

6: Lasso M, Cerón I. [Mirtazapine and antiretroviral therapy in the treatment of progressive multifocal leukoencephalopathy associated with HIV-1 infection: report of a case and review of literature]. Rev Chilena Infectol. 2012 Apr;29(2):217-20. doi: 10.4067/S0716-10182012000200016. Review. Spanish. PubMed PMID: 22689039.

7: Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2. Review. PubMed PMID: 22161405; PubMed Central PMCID: PMC4158430.

8: Phan SV, Kreys TJ. Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy. 2011 Oct;31(10):1017-30. doi: 10.1592/phco.31.10.1017. Review. PubMed PMID: 21950644.

9: Wichniak A, Wierzbicka A. [The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine]. Pol Merkur Lekarski. 2011 Jul;31(181):65-70. Review. Polish. PubMed PMID: 21870714.

10: Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011 Jul 30;378(9789):403-11. doi: 10.1016/S0140-6736(11)60830-1. Epub 2011 Jul 19. Review. PubMed PMID: 21764118.

11: Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother. 2011 Jul;12(10):1623-32. doi: 10.1517/14656566.2011.585459. Epub 2011 Jun 6. Review. PubMed PMID: 21644844.

12: Li TC, Shiah IS, Sun CJ, Tzang RF, Huang KC, Lee WK. Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. J ECT. 2011 Jun;27(2):165-7. doi: 10.1097/YCT.0b013e3181e63346. Review. PubMed PMID: 21602639.

13: Spiegel DR, Kolb R. Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine. Clin Neuropharmacol. 2011 Jan-Feb;34(1):36-8. doi: 10.1097/WNF.0b013e318209cef2. Review. PubMed PMID: 21242743.

14: Álvarez E, Viñas F. Mirtazapine in combination. Actas Esp Psiquiatr. 2010 Mar-Apr;38(2):121-8. Review. PubMed PMID: 21361055.

15: Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA; MANGA (Meta-Analysis of New Generation Antidepressants) Study Group. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs. 2010 Jan;24(1):35-53. doi: 10.2165/11319480-000000000-00000. Review. PubMed PMID: 20030418.

16: Fox CB, Treadway AK, Blaszczyk AT, Sleeper RB. Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly. Pharmacotherapy. 2009 Apr;29(4):383-97. doi: 10.1592/phco.29.4.383. Review. PubMed PMID: 19323618.

17: Rihmer Z, Purebl G. [Mirtazapine--pharmacologic action and clinical advantages]. Neuropsychopharmacol Hung. 2009 Mar;11(1):35-40. Review. Hungarian. PubMed PMID: 19731817.

18: Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23(5):427-52. doi: 10.2165/00023210-200923050-00006. Review. PubMed PMID: 19453203.

19: Howland RH. Understanding the clinical profile of a drug on the basis of its pharmacology: mirtazapine as an example. J Psychosoc Nurs Ment Health Serv. 2008 Dec;46(12):19-23. Review. PubMed PMID: 19133491.

20: Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25. Review. PubMed PMID: 16342227.